Galapagos initiates Proof-of-Mechanism clinical study for candidate cachexia drug GLPG0492

21-Jul-2011 - Galapagos NV announced that it has started a Phase I Proof-of-Mechanism study for GLPG0492, a candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. This Proof-of-Mechanism study follows the positive outcome of the ...

Galapagos initiates Phase II trial for GLPG0634

Proof-of-Concept study designed to assess efficacy in rheumatoid arthritis patients by year end

10-Jun-2011 - Galapagos NV announced that it has started a Phase II clinical study for GLPG0634, a novel Janus kinase (JAK) inhibitor being developed for inflammatory conditions, such as rheumatoid arthritis (RA). In this clinical trial, the efficacy and safety of GLPG0634 will be tested in RA patients, with ...

Galapagos discontinues Phase II trial for GLPG0259, focuses resources on other rheumatoid arthritis programs

19-Apr-2011 - Galapagos NV announced that it will discontinue its Phase II clinical trial for GLPG0259 in rheumatoid arthritis. This decision is based on the outcome of a planned interim analysis which did not support the continuation of GLPG0259's development for rheumatoid arthritis. An Interim Review ...

Galapagos starts Phase Ib clinical study in cancer patients

16-Mar-2011 - Galapagos NV announced that it has started a Phase Ib clinical study for GLPG0187, a novel drug being developed for metastatic cancer. In this clinical study, Galapagos plans to assess the safety and explore the preliminary efficacy of GLPG0187 in cancer patients. "GLPG0187 marks the third ...

Argenta delivers preclinical candidate for Wellcome Trust funded, anti-aging project

20-Oct-2010 - Argenta, a service division of Galapagos NV, announced that it recently concluded contract research support to the University of Edinburgh for a Wellcome Trust funded Seeding Drug Discovery Initiative (SDDI) project resulting in the successful identification of a preclinical candidate. The ...

Galapagos starts Phase II clinical trial in rheumatoid arthritis patients

29-Sep-2010 - Galapagos NV announced that it has started a Phase II clinical study for the Company's flagship program GLPG0259, a novel drug being developed for rheumatoid arthritis (RA). In this clinical trial, the safety and efficacy of this novel candidate drug will be tested in RA patients. Galapagos ...

Galapagos initiates Phase I study for JAK inhibitor GLPG0634

09-Aug-2010 - Galapagos NV (GLPG) announced that it has acquired from GlaxoSmithKline (GSK) the full rights to GLPG0634, a small molecule drug previously part of the Company's arthritis alliance with GSK. Galapagos is initiating a Phase I clinical trial with this selective JAK inhibitor. GLPG0634 is an ...

Servier and Galapagos initiate strategic alliance in osteoarthritis

02-Jul-2010 - Servier and Galapagos NV announced that they have entered into a multi-year strategic alliance to develop new therapies in osteoarthritis (OA). The alliance between Servier and Galapagos builds on novel OA drug targets discovered by Galapagos through its proprietary platform. Galapagos will ...

Galapagos initiates clinical studies with GLPG0492, a candidate drug for cachexia

21-May-2010 - Galapagos NV announced that it has initiated a first-in-human trial for GLPG0492, its candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. GLPG0492 is an orally available small molecule that Galapagos has developed ...

Galapagos and Roche expand COPD alliance

12-May-2010 - Galapagos NV announced that it has expanded its global multi-year strategic alliance with Roche to develop potential new therapies in COPD (chronic obstructive pulmonary disease). The partners have increased the number of antibody targets in the alliance. In addition, these targets can now also ...